Suppression of coronavirus replication by cyclophilin inhibitors.
Identifieur interne : 001095 ( PubMed/Checkpoint ); précédent : 001094; suivant : 001096Suppression of coronavirus replication by cyclophilin inhibitors.
Auteurs : Yoshikazu Tanaka [Japon] ; Yuka Sato ; Takashi SasakiSource :
- Viruses [ 1999-4915 ] ; 2013.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Cyclophilines.
- métabolisme : Cyclophilines.
- pharmacologie : Antiviraux, Ciclosporine.
- physiologie : Coronavirus.
- Interactions hôte-pathogène, Réplication virale.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Cyclophilins.
- chemical , metabolism : Cyclophilins.
- chemical , pharmacology : Antiviral Agents, Cyclosporine.
- physiology : Coronavirus.
- Host-Pathogen Interactions, Virus Replication.
Abstract
Coronaviruses infect a variety of mammalian and avian species and cause serious diseases in humans, cats, mice, and birds in the form of severe acute respiratory syndrome (SARS), feline infectious peritonitis (FIP), mouse hepatitis, and avian infectious bronchitis, respectively. No effective vaccine or treatment has been developed for SARS-coronavirus or FIP virus, both of which cause lethal diseases. It has been reported that a cyclophilin inhibitor, cyclosporin A (CsA), could inhibit the replication of coronaviruses. CsA is a well-known immunosuppressive drug that binds to cellular cyclophilins to inhibit calcineurin, a calcium-calmodulin-activated serine/threonine-specific phosphatase. The inhibition of calcineurin blocks the translocation of nuclear factor of activated T cells from the cytosol into the nucleus, thus preventing the transcription of genes encoding cytokines such as interleukin-2. Cyclophilins are peptidyl-prolyl isomerases with physiological functions that have been described for many years to include chaperone and foldase activities. Also, many viruses require cyclophilins for replication; these include human immunodeficiency virus, vesicular stomatitis virus, and hepatitis C virus. However, the molecular mechanisms leading to the suppression of viral replication differ for different viruses. This review describes the suppressive effects of CsA on coronavirus replication.
DOI: 10.3390/v5051250
PubMed: 23698397
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23698397Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Suppression of coronavirus replication by cyclophilin inhibitors.</title><author><name sortKey="Tanaka, Yoshikazu" sort="Tanaka, Yoshikazu" uniqKey="Tanaka Y" first="Yoshikazu" last="Tanaka">Yoshikazu Tanaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary & Life Science University, Tokyo 180-8602, Japan. ytanaka@nvlu.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary & Life Science University, Tokyo 180-8602</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sato, Yuka" sort="Sato, Yuka" uniqKey="Sato Y" first="Yuka" last="Sato">Yuka Sato</name></author><author><name sortKey="Sasaki, Takashi" sort="Sasaki, Takashi" uniqKey="Sasaki T" first="Takashi" last="Sasaki">Takashi Sasaki</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23698397</idno><idno type="pmid">23698397</idno><idno type="doi">10.3390/v5051250</idno><idno type="wicri:Area/PubMed/Corpus">001193</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001193</idno><idno type="wicri:Area/PubMed/Curation">001193</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001193</idno><idno type="wicri:Area/PubMed/Checkpoint">001095</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001095</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Suppression of coronavirus replication by cyclophilin inhibitors.</title><author><name sortKey="Tanaka, Yoshikazu" sort="Tanaka, Yoshikazu" uniqKey="Tanaka Y" first="Yoshikazu" last="Tanaka">Yoshikazu Tanaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary & Life Science University, Tokyo 180-8602, Japan. ytanaka@nvlu.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary & Life Science University, Tokyo 180-8602</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sato, Yuka" sort="Sato, Yuka" uniqKey="Sato Y" first="Yuka" last="Sato">Yuka Sato</name></author><author><name sortKey="Sasaki, Takashi" sort="Sasaki, Takashi" uniqKey="Sasaki T" first="Takashi" last="Sasaki">Takashi Sasaki</name></author></analytic><series><title level="j">Viruses</title><idno type="eISSN">1999-4915</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term><term>Coronavirus (physiology)</term><term>Cyclophilins (antagonists & inhibitors)</term><term>Cyclophilins (metabolism)</term><term>Cyclosporine (pharmacology)</term><term>Host-Pathogen Interactions</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term><term>Ciclosporine (pharmacologie)</term><term>Coronavirus (physiologie)</term><term>Cyclophilines (antagonistes et inhibiteurs)</term><term>Cyclophilines (métabolisme)</term><term>Interactions hôte-pathogène</term><term>Réplication virale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cyclophilins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cyclophilins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Cyclosporine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cyclophilines</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cyclophilines</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Ciclosporine</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Interactions hôte-pathogène</term><term>Réplication virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronaviruses infect a variety of mammalian and avian species and cause serious diseases in humans, cats, mice, and birds in the form of severe acute respiratory syndrome (SARS), feline infectious peritonitis (FIP), mouse hepatitis, and avian infectious bronchitis, respectively. No effective vaccine or treatment has been developed for SARS-coronavirus or FIP virus, both of which cause lethal diseases. It has been reported that a cyclophilin inhibitor, cyclosporin A (CsA), could inhibit the replication of coronaviruses. CsA is a well-known immunosuppressive drug that binds to cellular cyclophilins to inhibit calcineurin, a calcium-calmodulin-activated serine/threonine-specific phosphatase. The inhibition of calcineurin blocks the translocation of nuclear factor of activated T cells from the cytosol into the nucleus, thus preventing the transcription of genes encoding cytokines such as interleukin-2. Cyclophilins are peptidyl-prolyl isomerases with physiological functions that have been described for many years to include chaperone and foldase activities. Also, many viruses require cyclophilins for replication; these include human immunodeficiency virus, vesicular stomatitis virus, and hepatitis C virus. However, the molecular mechanisms leading to the suppression of viral replication differ for different viruses. This review describes the suppressive effects of CsA on coronavirus replication.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23698397</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Suppression of coronavirus replication by cyclophilin inhibitors.</ArticleTitle><Pagination><MedlinePgn>1250-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v5051250</ELocationID><Abstract><AbstractText>Coronaviruses infect a variety of mammalian and avian species and cause serious diseases in humans, cats, mice, and birds in the form of severe acute respiratory syndrome (SARS), feline infectious peritonitis (FIP), mouse hepatitis, and avian infectious bronchitis, respectively. No effective vaccine or treatment has been developed for SARS-coronavirus or FIP virus, both of which cause lethal diseases. It has been reported that a cyclophilin inhibitor, cyclosporin A (CsA), could inhibit the replication of coronaviruses. CsA is a well-known immunosuppressive drug that binds to cellular cyclophilins to inhibit calcineurin, a calcium-calmodulin-activated serine/threonine-specific phosphatase. The inhibition of calcineurin blocks the translocation of nuclear factor of activated T cells from the cytosol into the nucleus, thus preventing the transcription of genes encoding cytokines such as interleukin-2. Cyclophilins are peptidyl-prolyl isomerases with physiological functions that have been described for many years to include chaperone and foldase activities. Also, many viruses require cyclophilins for replication; these include human immunodeficiency virus, vesicular stomatitis virus, and hepatitis C virus. However, the molecular mechanisms leading to the suppression of viral replication differ for different viruses. This review describes the suppressive effects of CsA on coronavirus replication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshikazu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary & Life Science University, Tokyo 180-8602, Japan. ytanaka@nvlu.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021983">Cyclophilins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021983" MajorTopicYN="N">Cyclophilins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23698397</ArticleId><ArticleId IdType="pii">v5051250</ArticleId><ArticleId IdType="doi">10.3390/v5051250</ArticleId><ArticleId IdType="pmc">PMC3712306</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3226-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19451286</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Aug 10;3(8):e109</Citation><ArticleIdList><ArticleId IdType="pubmed">17696607</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Aug;5(8):e1000546</Citation><ArticleIdList><ArticleId IdType="pubmed">19680534</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Monit. 2009 Nov;15(11):RA221-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19865066</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2010 Feb;54(2):660-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19933795</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Feb 5;397(1):43-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19932913</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 May 26;28 Suppl 2:B51-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20510744</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010;6(9):e1001118</Citation><ArticleIdList><ArticleId IdType="pubmed">20886100</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ J. 2010 Nov;74(11):2249-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20962430</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(10):e13687</Citation><ArticleIdList><ArticleId IdType="pubmed">21060866</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2011 Mar 15;411(2):374-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21295323</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2011 Mar 30;412(1):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21281954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2011 Nov;92(Pt 11):2542-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21752960</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2011 Oct;7(10):e1002331</Citation><ArticleIdList><ArticleId IdType="pubmed">22046132</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Res. 2012;43:41</Citation><ArticleIdList><ArticleId IdType="pubmed">22546085</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2012 Aug 10;424(4):647-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22814107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Feb;87(3):1454-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23152531</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 May 22;98(11):6360-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11353871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Jun 21;277(25):22959-65</Citation><ArticleIdList><ArticleId IdType="pubmed">11943775</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2003 Jul;84(Pt 7):1687-99</Citation><ArticleIdList><ArticleId IdType="pubmed">12810862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Aug;77(16):9052-68</Citation><ArticleIdList><ArticleId IdType="pubmed">12885921</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 May 21;279(21):22322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15016823</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Vet Res. 1981 Mar;42(3):368-77</Citation><ArticleIdList><ArticleId IdType="pubmed">6267960</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1987 Sep;17(9):1359-65</Citation><ArticleIdList><ArticleId IdType="pubmed">3308488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1992 Jan 2;355(6355):33-45</Citation><ArticleIdList><ArticleId IdType="pubmed">1731198</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8421688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1993 Jun 18;73(6):1067-78</Citation><ArticleIdList><ArticleId IdType="pubmed">8513493</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Apr;69(4):2451-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7884893</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 1998 Feb;4(2):127-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9570313</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2004;10(32):4081-101</Citation><ArticleIdList><ArticleId IdType="pubmed">15579090</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Mar 1;191(5):755-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15688292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2005 Jul 1;19(1):111-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15989969</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2005;6(7):226</Citation><ArticleIdList><ArticleId IdType="pubmed">15998457</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Sep 30;340(2):209-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16051301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Nov;79(22):14122-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16254347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2006 Apr;43(4):761-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16557546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Nov;81(21):11620-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17715225</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18212100</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Immunol Immunopathol. 2008 May 15;123(1-2):172-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18395801</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):946-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18407825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Sep 26;283(39):26312-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18667415</ArticleId></ArticleIdList></Reference><Reference><Citation>J Feline Med Surg. 2009 Apr;11(4):225-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19254859</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19430490</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2006 May 12;343(3):879-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16564500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 May 11;441(7090):244-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16688178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(1):20-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16928755</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Jun;3(6):e88</Citation><ArticleIdList><ArticleId IdType="pubmed">17590083</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Jul;5(7):e1000524</Citation><ArticleIdList><ArticleId IdType="pubmed">19629175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><noCountry><name sortKey="Sasaki, Takashi" sort="Sasaki, Takashi" uniqKey="Sasaki T" first="Takashi" last="Sasaki">Takashi Sasaki</name><name sortKey="Sato, Yuka" sort="Sato, Yuka" uniqKey="Sato Y" first="Yuka" last="Sato">Yuka Sato</name></noCountry><country name="Japon"><region name="Région de Kantō"><name sortKey="Tanaka, Yoshikazu" sort="Tanaka, Yoshikazu" uniqKey="Tanaka Y" first="Yoshikazu" last="Tanaka">Yoshikazu Tanaka</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001095 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001095 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23698397
|texte= Suppression of coronavirus replication by cyclophilin inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23698397" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |